BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zandee WT, de Herder WW. The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines. Neuroendocrinology 2018;106:357-65. [PMID: 29320780 DOI: 10.1159/000486096] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Basu S, Parghane R, Ranade R, Thapa P, Ramaswamy A, Ostwal V, Sirohi B, Panda D, Shrikhande SV. Peptide Receptor Radionuclide Therapy in the Management of Neuroendocrine Tumors (Neoplasms): Fundamentals and Salient Clinical Practice Points for Medical Oncologists. Indian Journal of Medical and Paediatric Oncology 2021;40:165-71. [DOI: 10.4103/ijmpo.ijmpo_161_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Apitzsch J, Verburg FA, Mottaghy F, Heinzel A. Use of full-dose contrast-enhanced CT for extrahepatic staging using Gallium-68-DOTATATE PET/CT in patients with neuroendocrine tumors. Diagn Interv Radiol 2021;27:573-9. [PMID: 34313245 DOI: 10.5152/dir.2021.19424] [Reference Citation Analysis]
3 Tarquini M, Ambrosio MR, Albertelli M, de Souza PB, Gafà R, Gagliardi I, Carnevale A, Franceschetti P, Zatelli MC. A tool to predict survival in stage IV entero-pancreatic NEN. J Endocrinol Invest 2021;44:1185-92. [PMID: 32892316 DOI: 10.1007/s40618-020-01404-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Lesén E, Björstad Å, Björholt I, Marlow T, Bollano E, Feuilly M, Marteau F, Welin S, Elf AK, Johanson V. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study. Scand J Gastroenterol 2018;53:1509-18. [PMID: 30449217 DOI: 10.1080/00365521.2018.1531653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
5 Desai GS, Pande P, Chhabra V, Shah RC, Jagannath P. Multimodality management, recurrence patterns, and long-term outcome of gastroenteropancreatic neuroendocrine neoplasms: Progress over 17 years. Indian J Gastroenterol 2019;38:399-410. [PMID: 31802438 DOI: 10.1007/s12664-019-00957-4] [Reference Citation Analysis]
6 Saravana-Bawan B, Bajwa A, Paterson J, McEwan AJB, McMullen TPW. Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors: A Meta-analysis. Clin Nucl Med 2019;44:719-27. [PMID: 31205149 DOI: 10.1097/RLU.0000000000002646] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
7 Primavesi F, Klieser E, Cardini B, Marsoner K, Fröschl U, Thalhammer S, Fischer I, Hauer A, Urbas R, Kiesslich T, Neureiter D, Zitt M, Klug R, Wundsam H, Sellner F, Karner J, Függer R, Cakar-Beck F, Kornprat P, Öfner D, Stättner S; ASSO pNEN Study Group. Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group. Eur J Surg Oncol 2019;45:198-206. [PMID: 30262324 DOI: 10.1016/j.ejso.2018.08.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
8 Hou J, Yang Y, Chen N, Chen D, Hu S. Prognostic Value of Volume-Based Parameters Measured by SSTR PET/CT in Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:771912. [PMID: 34901087 DOI: 10.3389/fmed.2021.771912] [Reference Citation Analysis]
9 Shiozaki H, Shirai Y, Horiuchi T, Yasuda J, Furukawa K, Onda S, Gocho T, Shiba H, Ikegami T. Feasible laparoscopic distal pancreatectomy for pancreatic neuroendocrine tumors. Mol Clin Oncol 2021;14:111. [PMID: 33903817 DOI: 10.3892/mco.2021.2273] [Reference Citation Analysis]
10 Yazdanpanah O, Surapaneni S, Shanah L, Kabashneh S. Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors: A Comprehensive Literature Review. Cureus 2021;13:e14006. [PMID: 33884247 DOI: 10.7759/cureus.14006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Haddad T, Fard-Esfahani A, Vali R. A review of pediatric neuroendocrine tumors, their detection, and treatment by radioisotopes. Nucl Med Commun 2021;42:21-31. [PMID: 33044400 DOI: 10.1097/MNM.0000000000001305] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Zheng H, Zhou S, Tang W, Wang Q, Zhang X, Jin X, Yuan Y, Fu J. p.L105Vfs mutation in a family with thymic neuroendocrine tumor combined with MEN1: a case report. BMC Neurol 2020;20:76. [PMID: 32126984 DOI: 10.1186/s12883-020-01659-7] [Reference Citation Analysis]
13 Karfis I, Marin G, Levillain H, Drisis S, Muteganya R, Critchi G, Taraji-Schiltz L, Guix CA, Shaza L, Elbachiri M, Mans L, Machiels G, Hendlisz A, Flamen P. Prognostic value of a three-scale grading system based on combining molecular imaging with 68Ga-DOTATATE and 18F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias.Oncotarget. 2020;11:589-599. [PMID: 32110279 DOI: 10.18632/oncotarget.27460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Gamboa AC, Liu Y, Lee RM, Zaidi MY, Staley CA, Kooby DA, Winer JH, Shah MM, Russell MC, Cardona K, Maithel SK. Duodenal neuroendocrine tumors: Somewhere between the pancreas and small bowel? J Surg Oncol 2019;120:1293-301. [PMID: 31621090 DOI: 10.1002/jso.25731] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
15 Søreide JA, Kvaløy JT, Lea D, Sandvik OM, Al-Saiddi M, Haslerud TM, Garresori H, Karlsen LN, Gudlaugsson E, Søreide K. The overriding role of surgery and tumor grade for long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based cohort study. Cancer Rep (Hoboken) 2021;:e1462. [PMID: 34105314 DOI: 10.1002/cnr2.1462] [Reference Citation Analysis]
16 Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Gálvez Moreno MA, Luque RM, Castaño JP, de Herder WW, Feelders RA. Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs 2019;79:21-42. [PMID: 30560479 DOI: 10.1007/s40265-018-1033-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
17 Mesolella M, Allosso S, Varricchio S, Russo D, Pignatiello S, Buono S, Motta G. Small-Cell Carcinoma of Nasopharynx: A Case Report of Unusual Localization. Ear Nose Throat J 2020;:145561320973780. [PMID: 33371727 DOI: 10.1177/0145561320973780] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Cuthbertson DJ, Barriuso J, Lamarca A, Manoharan P, Westwood T, Jaffa M, Fenwick SW, Nuttall C, Lalloo F, Prachalias A, Pizanias M, Wieshmann H, McNamara MG, Hubner R, Srirajaskanthan R, Vivian G, Ramage J, Weickert MO, Pritchard DM, Vinjamuri S, Valle J, Yip VS. The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours. Front Endocrinol (Lausanne) 2021;12:654975. [PMID: 34163434 DOI: 10.3389/fendo.2021.654975] [Reference Citation Analysis]
19 Klomp MJ, Dalm SU, de Jong M, Feelders RA, Hofland J, Hofland LJ. Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer. Rev Endocr Metab Disord 2021;22:495-510. [PMID: 33085037 DOI: 10.1007/s11154-020-09607-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Xu Z, Wang L, Dai S, Chen M, Li F, Sun J, Luo F. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. JAMA Netw Open 2021;4:e2124750. [PMID: 34554237 DOI: 10.1001/jamanetworkopen.2021.24750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Nilica B, Svirydenka A, Fritz J, Bayerschmidt S, Kroiss AS, Gruber L, Virgolini IJ. Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning. A retrospective analysis. Rev Esp Med Nucl Imagen Mol 2021:S2253-654X(21)00062-7. [PMID: 34384731 DOI: 10.1016/j.remn.2021.03.004] [Reference Citation Analysis]